

IN THE CLAIMS

1-35. [Cancelled]

36. [Currently Amended] ~~The polypeptide of claim 34, wherein the lysosomal enzyme is A~~
polypeptide comprising a soluble lysosomal enzyme operably linked to a PTD, wherein
the polypeptide is biologically active. ¹¹²

37. [Original] The polypeptide of claim 36, wherein the soluble lysosomal enzyme is β -glucuronidase, pepstatin insensitive protease or palmitoyl protein thioesterase.

38. [Previously Amended] The polypeptide of claim 36, wherein the soluble lysosomal enzyme is β -glucuronidase.

39. [Currently Amended] ~~The polypeptide of claim 34, wherein the polypeptide is A~~
polypeptide comprising a naturally secreted protein operably linked to a PTD.

40. [Original] The polypeptide of claim 39, wherein the secreted protein is a growth factor or an anti-neoplastic protein.

41. [Original] The polypeptide of claim 40, wherein the growth factor is GDNF, NGF, BDNF, or NT3.

42. [Original] The polypeptide of claim 40, wherein the anti-neoplastic protein is an inhibitor of neovascularization, cell migration, or cell proliferation.

43. [Currently Amended] ~~The polypeptide of claim 34, wherein the polypeptide is A~~
polypeptide comprising a nuclear protein operably linked to a PTD.

44. [Original] The polypeptide of claim 43, wherein the nuclear protein is a transcription factor.

~~45.~~ [Currently Amended] ~~The polypeptide of claim 34, wherein the polypeptide is A~~
polypeptide comprising a cytoplasmic protein operably linked to a PTD.

46. [Original] The polypeptide of claim 45, wherein the cytoplasmic protein is a cytotoxic agent.

~~47.~~ [Currently Amended] The polypeptide of claim ~~36~~ 34, wherein the PTD is Tat PTD.

~~48.~~ [Original] The polypeptide of claim 47, wherein the Tat PTD is Tat₄₇₋₅₇.

49-61. [Cancelled]

~~62.~~ [Currently Amended] The polypeptide of claim ~~36~~ 34, wherein the polypeptide is enzymatically active.

~~63.~~ [New] The polypeptide of claim 39, wherein the polypeptide is enzymatically active.

64. [New] The polypeptide of claim 43, wherein the polypeptide is enzymatically active.

~~65.~~ [New] The polypeptide of claim 45, wherein the polypeptide is enzymatically active.

~~66.~~ [New] The polypeptide of claim 39, wherein the PTD is Tat PTD.

~~67.~~ [New] The polypeptide of claim 66, wherein the Tat PTD is Tat₄₇₋₅₇.

68. [New] The polypeptide of claim 43, wherein the PTD is Tat PTD.
69. [New] The polypeptide of claim 68, wherein the Tat PTD is Tat₄₇₋₅₇.
70. [New] The polypeptide of claim 45, wherein the PTD is Tat PTD.
- ~~71.~~ [New] The polypeptide of claim 70, wherein the Tat PTD is Tat₄₇₋₅₇.
72. [New] The polypeptide of claim 36, wherein the polypeptide is expressed from an expression vector located *in situ* in a brain cell of a patient.
73. [New] The polypeptide of claim 39, wherein the polypeptide is expressed from an expression vector located *in situ* in a brain cell of a patient.
- B¹. 74. [New] The polypeptide of claim 43, wherein the polypeptide is expressed from an expression vector located *in situ* in a brain cell of a patient.
75. [New] The polypeptide of claim 45, wherein the polypeptide is expressed from an expression vector located *in situ* in a brain cell of a patient.
76. [New] The polypeptide of claim 39, wherein the polypeptide is biologically active.
77. [New] The polypeptide of claim 43, wherein the polypeptide is biologically active.
78. [New] The polypeptide of claim 45, wherein the polypeptide is biologically active.
-